Record #878931

SenseGuard

A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Coordinator	NanoVation-GS
Grant period	2020-04-01 - 2023-03-31
Funding body	European Union
Call number	H2020-EIC-SMEInst-2018-2020-3
Grant number	946598
Identifier	G:(EU-Grant)946598

Note: Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become one of the leading causes of death by 2030. Nevertheless, COPD patients lack of a constant and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems. SenseGuard is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing. NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes and is run by an experienced and multi-disciplinary team of 12 people. During the proposed Phase 2 project, NanoVation will finalise the development of the SenseGuard device and validate its efficacy and safety in dedicated clinical studies.

Recent Publications

There are no publications

Record created 2020-09-04, last modified 2023-02-10

Similar records

Rate this document:

(Not yet reviewed)

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

guest :: login JuSER
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help